About: Retinopathy of prematurity in Rwanda: a prospective multi-centre study following introduction of screening and treatment services

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Retinopathy of prematurity in Rwanda: a prospective multi-centre study following introduction of screening and treatment services Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Retinopathy of prematurity in Rwanda: a prospective multi-centre study following introduction of screening and treatment services
Creator	Casteels, Ingele Conard, Craig De Smedt, Stefan Muhizi, Charles Mutangana, Francis Ngambe, Tharcisse Noë, Piet Nsabimana, Hovaire Godelieve Mudereva, • Kumwami, • Stephenson Musiime, • Tuyisenge, • Yannick Fonteyne, •
Source	PMC
abstract	OBJECTIVES: To investigate risk factors for retinopathy of prematurity (ROP) in a newly established ROP screening and management programme in Rwanda, Africa. METHODS: In this multi-centre prospective study 795/2222 (36%) babies fulfilled the inclusion criteria (gestational age (GA) < 35 weeks or birth weight (BW) < 1800 g or unstable clinical course), 424 (53%) of whom were screened for ROP. 270 died before the first screening. ROP and treatment-warranted ROP were classified using the revised International Classification of ROP (2005). Data on maternal and perinatal risk factors were collected from daily neonatal notes. RESULTS: 31 babies (7.3%, CI 5.0–10.2) developed any ROP, 13 of whom (41.9%, CI 24.5–60.9) required treatment. ROP was seen in six neonates with GA > 30 weeks and BW > 1500 g, one of whom required treatment. In univariate analysis the following were associated with any ROP: increasing number of days on supplemental oxygen (OR 2.1, CI 1.5–3.0, P < 0.001), low GA (OR 3.4, CI 1.8–6.4, P < 0.001), low BW (OR 2.3, CI 1.5–3.4, P < 0.001), at least one episode of hyperglycaemia ≥ 150 mg/dl (OR 6.6, CI 2.0–21.5, P < 0.001), blood transfusion (OR 3.5, CI 1.6–7.4, P < 0.001) or sepsis (OR 3.2, CI 1.2–8.6, P = 0.01). In multivariate analysis longer exposure to supplemental oxygen (OR 2.1, CI 1.2–3.6, P = 0.01) and hyperglycaemia (OR 3.5, CI 1.0–12.4, P = 0.05) remained significant. CONCLUSIONS: ROP has become an emerging health problem in Rwanda, requiring programmes for screening and treatment. ROP screening is indicated beyond the 2013 American Academy guidelines. Improved quality of neonatal care, particularly oxygen delivery and monitoring is needed.
has issue date	2019-07-30(xsd:dateTime)
bibo:doi	10.1038/s41433-019-0529-5
bibo:pmid	31363176
has license	no-cc
sha1sum (hex)	a6ac15bca4e99e65999aa106c962a44912537132
schema:url	https://doi.org/10.1038/s41433-019-0529-5
resource representing a document's title	Retinopathy of prematurity in Rwanda: a prospective multi-centre study following introduction of screening and treatment services
has PubMed Central identifier	PMC7182562
has PubMed identifier	31363176
schema:publication	Eye (Lond)
resource representing a document's body	covid:a6ac15bca4e99e65999aa106c962a44912537132#body_text
is schema:about of	named entity 'screening' named entity 'multivariate analysis' named entity 'babies' named entity 'risk factors' named entity 'Retinopathy' named entity '1.6' named entity 'DAYS' named entity '3.5' named entity 'REQUIRED' named entity 'SEPSIS' named entity '150' named entity '2-3' named entity 'UNIVARIATE ANALYSIS' named entity 'screening' named entity 'perinatal' named entity 'problem' named entity 'management' named entity 'screened' named entity 'hyperglycaemia' named entity 'Africa' named entity '2.1' named entity 'mg/dl' named entity '0.01' named entity 'ROP' named entity 'supplemental oxygen' named entity 'supplemental oxygen' named entity 'ROP' named entity 'Rwanda' named entity 'Rwanda' named entity '2.1' named entity 'risk factors' named entity 'ROP' named entity '1.2' named entity 'neonatal care' named entity 'blood transfusion' named entity 'treatment services' named entity 'risk factor' named entity 'oxygen' named entity 'red blood cells' named entity 'vascularisation' named entity 'sub-Saharan Africa' named entity 'preterm infants' named entity 'level of significance' named entity 'ROP' named entity '5.7' named entity 'ROP' named entity 'risk factors' named entity 'demographic' named entity 'ROP' named entity 'pathogenesis' named entity 'neonatal' named entity 'ROP' named entity 'ROP' named entity 'vascularisation' named entity 'visually impaired' named entity 'Ophthalmology' named entity 'follow-up' named entity 'eye examination' named entity 'low-income countries' named entity 'ophthalmoscopy' named entity 'Asia' named entity 'inter-observer variability' named entity '0.01' named entity '2.1' named entity 'neonatal care' named entity 'eye condition' named entity 'ROP' named entity 'medical centres' named entity 'level of significance'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software